Ergoteles’s Co-Diagnostics CODX Stock Holding History

Ergoteles’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,553	Closed	-$1.13M	–	1274
2021 Q2	$1.13M	Buy	+4,553	New	+$1.17M	0.03%	471

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles's CODX Position: Q3 2021 in Review

Ergoteles sold out of Co-Diagnostics (CODX) in Q3 2021, closing a stake of 4,553 shares — an estimated $1.13M sold.

Ergoteles first reported a position in CODX in Q2 2021 and held it in 1 quarter. The position peaked at $1.13M in Q2 2021. 78 funds tracked by Wall St. Rank hold CODX as of Q3 2021.

Ergoteles reported no remaining Co-Diagnostics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 4,553 Co-Diagnostics shares in Q3 2021, an estimated $1.13M.
Ergoteles first reported a position in Co-Diagnostics in Q2 2021 and held it in 1 quarter.
Ergoteles's Co-Diagnostics position peaked at $1.13M in Q2 2021.
78 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.